

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

<p>Product</p> <p style="text-align: center;">LAUXERA HEALTHTECH – Share Class: IU - ISIN FR001400A6W4 sub-fund of the SICAV PERGAM FUNDS umbrella fund</p> <p style="text-align: center;">Organisme de Placement Collectif en Valeurs Mobilières (OPCVM) under French law and managed by PERGAM</p> <p>Manufacturer: PERGAM Site internet: www.pergam.net Contact: Call +33 (1) 53 57 72 00 for more information. Regulator: the Autorité des marchés financiers (AMF) is responsible for supervising PERGAM in relation to this Key Information Document. PERGAM was approved and is regulated in France by the AMF under the number GP01032. Date of production of the KID: 01/03/2024</p>

You are about to purchase a product that is not simple and may be difficult to understand.

What is this product?

Type: LAUXERA HEALTHTECH is an Organisme de Placement Collectif en Valeurs Mobilières (OPCVM) under French law and is subject to article L. 214-4 of the French Monetary and Financial Code. This OPCVM is a Société d'Investissement à Capital Variable (SICAV). The SICAV was approved by the AMF.

Term: The SICAV was created for a period of 99 years. The Manufacturer may terminate the Product early.

Objectives: Within the framework of discretionary management on the international equity markets, the management objective of the Lauxera HealthTech sub-fund is to achieve, over the recommended investment period of 5 years, an annual performance net of fees that exceeds that of the Bloomberg World Large, Mid & Small Cap Net Return Index EUR (Bloomberg code: WLSN Index), by investing in shares or equity-linked securities of international companies of all capitalization sizes operating in the healthcare sector. At least 90% of the assets are invested in shares.

This objective is combined with an extra-financial approach that takes into account environmental, social and governance (ESG) criteria.

The sub-fund's extra-financial objective complies with the provisions of Article 8 of the SFDR Regulation.

The performance objective is based on the achievement of market assumptions made by the management company and does not constitute a promise of return or performance of the sub-fund.

The manager implements discretionary management mainly exposed to the international equity markets of the health universe.

This sub-fund aims to achieve long-term capital gains by investing in a portfolio of shares or equity securities (certificates, equity securities, etc.) of international companies selected by the management team for their strategy inherent to the health sector.

The sub-fund is managed and has the objective over its recommended investment horizon to participate in the growth of international equity markets without indexing constraints.

At least 90% of the sub-fund's assets will be invested in equities (listed securities) from all sectors, of all capitalisation sizes (including a maximum of 30% of the assets in small capitalisation equities (market capitalisation of less than EUR 1 billion), from all geographical areas, including emerging countries within a limit of 10% of the net assets. Emerging countries generally include countries in Latin America, Asia, Africa, the Middle East and the developing regions of Eastern Europe.

The overall exposure (securities and derivatives) of the sub-fund to the equity markets shall be at least 60% of the net assets.

The sub-fund may invest up to the regulatory limits of 10% in units or shares of French or European UCITS, AIFs or investment funds that comply with the criteria set out in the French Monetary and Financial Code.

Due to its international equity investment nature, exposure to currency risk outside the Eurozone may reach 100% of the sub-fund's net assets.

Allocation of distributable amounts: accumulating

Intended retail investor: The SICAV is intended to long-term investors (more than 5 years), having a theoretical knowledge of equity market while agreeing to be exposed to a risk variation of the net asset value inherent to these markets. The SICAV may not be recommended to investors who will exit before the recommended holding period. The fund is not open to residents of the United States of America / US Persons.

Insurance: Non applicable.


Depositary: ODDO BHF SCA.

Further Information: information on the SICAV as well as the full prospectus and the current annual or semi-annual reports and other information can be obtained free of charge from the fund management company at middle@pergam.net. The current price is available at www.pergam.net.

Frequency of calculation of the net asset value and condition of subscription: subscription and redemption requests are received and centralised on each NAV calculation day (D) before 12 noon (Paris time). These requests are executed on the basis of the net asset value of D and calculated on the following business day (D+1). The net asset value is calculated daily except on days when the Paris stock exchange is closed (according to the official calendar of EURONEXT PARIS S.A.) and on public holidays in France.

What are the risks and what could I get in return?

Summary risk indicator



⚠ The risk indicator assumes you keep the product for 5 year(s). The actual risk may significantly differ if you opt to exit before the recommended holding period and you could get less in return. The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this SICAV as 4 out of 7, which is a medium risk class. This means that the fund's potential losses are medium and that poor market conditions could impact our capacity to pay you. You may not be able to sell-end your product easily or you may have to sell end your product at a price that significantly impacts on the performance of your product. The following risks impacting the SICAV but not included in the risk indicator may cause the net asset value to fall:

Counterparty risk: The counterparty risk arises from the sub-fund's use of forward financial instruments which are traded over-the-counter. These transactions potentially expose this sub-fund to the risk of default by one of the counterparties.

Risk of capital losses: The loss of capital occurs at the time of the sale of a unit for a price that is lower than the purchase price. The unit holder is warned that the capital initially invested may not be returned. The sub-fund does not benefit from any guarantee or capital protection.

Share risk: The sub-fund is exposed to a minimum of 60% in shares. If the shares or the indexes to which the portfolio is exposed decline, the asset value of the sub-fund may fall.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Performance Scenarios:

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

Recommended holding period : 5 years

Example Investment: 10.000 €

Scenarios:

If you exit after 1 year

If you exit after 5 years
(Recommended holding period)

Minimum: There is no minimum guaranteed return. You could lose some or all of your investment.

Stress scenarios	What you might get back after costs	3 157 €	3 175 €	This type of scenario occurred for an investment between 31/12/2021 and 31/10/2023.
	Average return each year	-68,43%	-20,50%	
Unfavourable scenarios	What you might get back after costs	8 072 €	6 587 €	This type of scenario occurred for an investment between 29/03/2019 and 01/03/2024.
	Average return each year	-19,28%	-8,01%	
Moderate scenarios	What you might get back after costs	10 596 €	14 326 €	This type of scenario occurred for an investment between 30/12/2016 and 31/12/2021.
	Average return each year	5,96%	7,46%	
Favourable scenarios	What you might get back after costs	14 321 €	20 173 €	
	Average return each year	43,21%	15,07%	

What happens if PERGAM is unable to pay out?

Losses are not covered by any investor compensation or guarantee scheme. The assets of the SICAV are held in one or more bank accounts opened in the name of the SICAV with the depositary. Consequently, the default of the PERGAM Company would not have an impact on the assets of the SICAV. The resale of shares, capital and income of the SICAV are not guaranteed by the Management Company.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The table shows the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods. We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods, we have assumed that the product performs as shown in the moderate scenario.
- 10 000 EUR is invested.

10 000 EUR invested scenario	If you exit after 1 year	If you exit after 5 years (Recommended holding period)
Total costs	371 €	1 491 €
Annual cost impact (*)	3,74 %	2,31 %

(*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 9,77% before costs and 7,46% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

Composition of costs:

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	2 % of the amount you pay-in when entering this investment. This includes the costs of distribution of your investment amount. This is the most you will be charged. The person selling you the product will inform you of the actual charge.	200 €
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	0 €
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1,6% of the value of your investment per year. This is an estimate based on actual costs over the last year.	160 €
Transaction costs	0,14% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	14 €
Incidental costs taken under specific conditions		
Performance fees	15% (including tax) of the sub-fund's outperformance compared to the Bloomberg World Large, Mid & Small Cap Net Return Index in USD (Bloomberg code: WLSN Index) over the financial year.	0 €

How long should I hold it and can I take money out early?

The recommended holding period for this product is 5 year(s), it has been selected due to the nature of the assets, equity and bond oriented, and because it is designed for a long-term investment horizon. It is recommended for asset diversification. If you disinvest earlier, there is a higher risk that you might get back only poor returns. You may request the redemption of securities generally on a daily basis.

How can I complain?

You can make have a complaint about the product (i), the manufacturer of the product (ii) or the person who recommended (iii) or sold the product to you, please contact as appropriate:

- If your complaint is related to the product or the manufacturer of the product, please contact the asset manager at PERGAM – 28 rue Bayard – 75008 Paris. A process is available at www.pergam.net.
- If your complaint is related to the person who recommended or sold the product to you, it may be appropriate for you to liaise directly with this person.

Under article L. 261-19 of the French Monetary and financial code, as last amicable settlement, you can contact the Mediator of the AMF at internet www.amf-france.org, or at: Le Médiateur - Autorité des marchés financiers - 17, place de la Bourse - 75082 PARIS CEDEX 02.

Other relevant information

This product is categorised as an « article 8 » under SDR regulation.

When this Product is used as a unit-linked vehicle in a life insurance or capitalisation contract, additional information about the contract in question, such as the costs associated with the contract – which are not included in the costs mentioned in this document, the person to contact in the event of a claim, and the procedures to follow if the insurance company fails, are provided in the contract's key information document, which must be given to you by your insurer or broker, or any other insurance intermediary, in compliance with their legal obligation.

Data related to past performance can be found for the last 1 year depending on the share class creation.

Information on past performance and previous performance scenario calculations can be found at: <https://www.pergam.net/fonds/>

Information on sustainability can be found at: <https://www.pergam.net/decouvrir-pergam/nos-engagements/>